10
NEWS
Lilly to integrate with Dexcom
Roche adds
Navify
Roche has announced the
introduction of the Navify brand to
its digital health portfolio, which
includes more than 30 digital
solutions for labs, hospitals, and
patients worldwide, though not
necessarily in diabetes care.
Navify digital solutions activate
insights that provide evidence
on how to optimize operational
processes and clinical decision
making in healthcare. The system
improves the interoperability of
digital infrastructure, uses advanced
analytics to deliver operational
excellence, improved workflows, and
patient-centric ways of working, and
generates advanced medical insights
to augment clinical decision support.
Roche will also use Navify
Marketplace to connect labs,
healthcare providers, and third-party
medtech companies.
Eli Lilly plans to introduce a personalized diabetes management platform
that integrates with technologies, including Dexcom's continuous glucose
monitoring (CGM) systems.
The platform, branded Tempo, features a reusable medical device that
attaches to Lilly's prefilled, disposable insulin pens and sends dose-related
data to the compatible app. According to Medtechdive, the platform has
three components: Tempo Smart Button, a device that records information
about the delivery of insulin and shares it via Bluetooth; TempoSmart, an app
Sernova's Cell
Pouch System is
an implantable and
scalable medical device
that forms a natural
environment in the
body for the long-term
survival and function
of therapeutic cells.
These cells release
necessary proteins
or factors missing
from the body to treat
chronic diseases,
including insulindependent
diabetes.
that records insulin dose information and enables patients to
share it with healthcare providers; and Tempo Pen, an insulin
delivery device.
Patients attach the button to Tempo Pen to send insulindose information
to TempoSmart. Capturing the data facilitates
medication reminders, personalised education resources and
feedback on blood glucose levels.
Lilly is enabling patients to bring more data into the system
by integrating with other devices, notably Dexcom CGM
systems and the Tempo blood glucose monitor.
Tempo can also sync data with wearable
devices from Fitbit, Garmin, Google Fit and the
Apple Health app.
www.lillytempo.com
that used in trials to date.
Sernova now plans to begin
enrollment for this second trial
and expects results to help guide
the design of its pivotal study to
support its anticipated biologics
license application (BLA) to
the FDA
According to www.
drugdeliverybusiness.com, the
University of Chicago Institutional
Review Board (IRB) has now approved
a further clinical trial to enables the
testing of up to seven patients, who
would receive Sernova's optimized
10-channel Cell Pouch with a 50%
greater islet capacity compared to